Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, April 2009, p. 1443-1449, Vol. 53, No. 4
0066-4804/09/$08.00+0 doi:10.1128/AAC.01146-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
,
Université Catholique de Louvain, Louvain Drug Research Institute, Unité de Pharmacologie Cellulaire et Moléculaire,1 Hôpital Erasme, Department of Microbiology, Laboratoire de Référence MRSA-Staphylocoques,2 Hôpital des Enfants Reine Fabiola, Département de Maladies Infectieuses Pédiatriques, Université Libre de Bruxelles, Brussels, Belgium3
Received 26 August 2008/ Returned for modification 10 December 2008/ Accepted 17 January 2009
In a companion paper (H. A. Nguyen et al., Antimicrob. Agents Chemother. 53:1434-1442, 2009), we showed that vancomycin, oxacillin, fusidic acid, clindamycin, linezolid, and daptomycin are poorly active against the intracellular form of a thymidine-dependent small-colony variant (SCV) strain isolated from a cystic fibrosis patient and that the activity of quinupristin-dalfopristin, moxifloxacin, rifampin, and oritavancin remains limited (2- to 3-log CFU reduction) compared to their extracellular activity. Antibiotic combination is a well-known strategy to improve antibacterial activity, which was examined here against an intracellular SCV strain using combinations with either rifampin or oritavancin. Time-kill curve analysis using either concentrations that caused a static effect for each antibiotic individually or concentrations corresponding to the maximum concentration in human serum showed largely divergent effects that were favorable when antibiotics were combined with rifampin at low concentrations only and with oritavancin at both low and high concentrations. The nature of the interaction between rifampin, oritavancin, and moxifloxacin was further examined using the fractional maximal effect method, which allows categorization of the effects of combinations when dose-effect relationships are not linear. Rifampin and oritavancin were synergistic at all concentration ratios investigated. Oritavancin and moxifloxacin were also synergistic but at high oritavancin concentrations only. Rifampin and moxifloxacin were additive. This approach may help in better assessing and improving the activity of antibiotics against intracellular SCV strains.
Published ahead of print on 2 February 2009.
Supplemental material for this article may be found at http://aac.asm.org/.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»